Mirae Asset Global Investments Co., Ltd. Ideaya Biosciences, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,880 shares of IDYA stock, worth $70,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,880

Previous 3,056 5.76%

Holding current value

$70,128

Previous $96,000 22.92%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$24.79 - $31.98 $4,363 - $5,628	-176 Reduced 5.76%	2,880 $74,000
Q3 2024 Oct 23, 2024	BUY	$30.37 - $43.05 $24,174 - $34,267	796 Added 35.22%	3,056 $96,000
Q2 2024 Jul 30, 2024	SELL	$34.37 - $43.46 $874,853 - $1.11 Million	-25,454 Reduced 91.85%	2,260 $79,000
Q1 2024 May 01, 2024	SELL	$34.2 - $47.13 $261,014 - $359,696	-7,632 Reduced 21.59%	27,714 $1.22 Million
Q4 2023 Jan 24, 2024	BUY	$24.59 - $35.83 $125,163 - $182,374	5,090 Added 16.82%	35,346 $1.26 Million
Q3 2023 Oct 26, 2023	SELL	$21.07 - $29.77 $1,390 - $1,964	-66 Reduced 0.22%	30,256 $816,000
Q2 2023 Aug 10, 2023	BUY	$13.33 - $25.53 $65,037 - $124,560	4,879 Added 19.18%	30,322 $712,000
Q1 2023 May 04, 2023	BUY	$13.49 - $18.72 $64,819 - $89,949	4,805 Added 23.28%	25,443 $349,000
Q4 2022 Feb 09, 2023	BUY	$14.47 - $18.17 $67,965 - $85,344	4,697 Added 29.46%	20,638 $374,000
Q3 2022 Nov 10, 2022	BUY	$9.24 - $15.79 $52,021 - $88,897	5,630 Added 54.6%	15,941 $238,000
Q2 2022 Jul 26, 2022	BUY	$8.28 - $13.88 $85,375 - $143,116	10,311 New	10,311 $143,000

Others Institutions Holding IDYA

# of Institutions

210

Shares Held

81M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.17B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Ideaya Biosciences, Inc. Transaction History